Youg Won Cho1, Mei Ling Song2. 1. Department of Neurology, Keimyung University, Daegu, South Korea. 2. Graduate School of Nursing, Keimyung University, Daegu, South Korea.
Abstract
STUDY OBJECTIVES: Long-term use of hypnotics runs the risk of dependency, and subjects usually experience difficulties in withdrawal. The objective of this study was to investigate the success of withdrawal using pregabalin and its efficacy on sleep in patients with hypnotic-dependent insomnia. METHODS: We enrolled patients with hypnotic-dependent insomnia who were 18 years or older. The starting dosage of pregabalin was 75 mg/day and was increased up to as much as 300 mg/day, depending on the individual patient's condition, while tapering off hypnotics. After 4 weeks of titration, the final dosage amount was maintained for at least another 4 weeks. Sleep and clinical variables were evaluated at baseline and after treatment, using the Korean versions of various sleep questionnaires as well as polysomnography. RESULTS:Forty subjects were enrolled, with a mean age of 52.0 ± 8.5 years, of whom 28 (70.0%) were women. Twenty-one (52.5%) subjects successfully withdrew from hypnotics. The duration of withdrawal was 42.1 ± 16.0 days (range: 27.0∼84.0). The mean pregabalin dose was 121.4 ± 69.0 mg/day (range: 75.0∼300.0). After pregabalin treatment, there was a significant improvement in the total score of the Pittsburgh Sleep Quality Index (15.0 ± 2.1, 8.9 ± 3.0, p < 0.001), and insomnia severity index (20.9 ± 4.3, 9.6 ± 4.4, p < 0.001); however, most of the sleep variables of the PSG showed no differences. The main adverse effects of pregabalin were nausea and dizziness. CONCLUSIONS: Our results showed pregabalin may be a promising candidate for withdrawal from hypnotics and improved sleep in patients with hypnotic-dependent insomnia.
RCT Entities:
STUDY OBJECTIVES: Long-term use of hypnotics runs the risk of dependency, and subjects usually experience difficulties in withdrawal. The objective of this study was to investigate the success of withdrawal using pregabalin and its efficacy on sleep in patients with hypnotic-dependent insomnia. METHODS: We enrolled patients with hypnotic-dependent insomnia who were 18 years or older. The starting dosage of pregabalin was 75 mg/day and was increased up to as much as 300 mg/day, depending on the individual patient's condition, while tapering off hypnotics. After 4 weeks of titration, the final dosage amount was maintained for at least another 4 weeks. Sleep and clinical variables were evaluated at baseline and after treatment, using the Korean versions of various sleep questionnaires as well as polysomnography. RESULTS: Forty subjects were enrolled, with a mean age of 52.0 ± 8.5 years, of whom 28 (70.0%) were women. Twenty-one (52.5%) subjects successfully withdrew from hypnotics. The duration of withdrawal was 42.1 ± 16.0 days (range: 27.0∼84.0). The mean pregabalin dose was 121.4 ± 69.0 mg/day (range: 75.0∼300.0). After pregabalin treatment, there was a significant improvement in the total score of the Pittsburgh Sleep Quality Index (15.0 ± 2.1, 8.9 ± 3.0, p < 0.001), and insomnia severity index (20.9 ± 4.3, 9.6 ± 4.4, p < 0.001); however, most of the sleep variables of the PSG showed no differences. The main adverse effects of pregabalin were nausea and dizziness. CONCLUSIONS: Our results showed pregabalin may be a promising candidate for withdrawal from hypnotics and improved sleep in patients with hypnotic-dependent insomnia.
Authors: Karl Rickels; Thomas M Shiovitz; Tanya S Ramey; Jerry J Weaver; Lloyd E Knapp; Jeffrey J Miceli Journal: Int Clin Psychopharmacol Date: 2012-05 Impact factor: 1.659
Authors: Panagiotis Oulis; George Konstantakopoulos; Anastasios V Kouzoupis; Vasilios G Masdrakis; Nikolaos A Karakatsanis; Evangelos Karapoulios; Konstantinos A Kontoangelos; George N Papadimitriou Journal: Hum Psychopharmacol Date: 2008-06 Impact factor: 1.672
Authors: Sanne de Haas; Andreas Otte; Al de Weerd; Gerard van Erp; Adam Cohen; Joop van Gerven Journal: J Clin Sleep Med Date: 2007-08-15 Impact factor: 4.062
Authors: Rainer Freynhagen; Miroslav Backonja; Stephan Schug; Gavin Lyndon; Bruce Parsons; Stephen Watt; Regina Behar Journal: CNS Drugs Date: 2016-12 Impact factor: 5.749